BioNTech will acquire Novartis’ GMP certified manufacturing facility in Marburg, Germany: with the site set to become one of the largest mRNA manufacturing plants in Europe.
Gene therapy developer, CombiGene, and CDMO, Cobra Biologics, have signed off on a deal to secure Good Manufacturing Practice (GMP) production of two essential plasmids needed for the manufacture of CombiGene's gene therapy, CG01.
To accelerate Covid-19 vaccine development, as well as upscale domestic manufacturing capabilities, the German government has announced a €750m (US$890m) fund to support the vaccine programs of three German developers, BioNTech, CureVac and IDT Biologika....
Merck's life science business division last week announced a US$65m expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin.
Thermo Fisher Scientific has opened a new bioprocessing collaboration center (BCC) adjacent to its biologics manufacturing facility in St Louis, Missouri.
Merck and Seattle Genetics have announced two strategic oncology collaborations: one to develop Seattle Genetics’ antibody-drug conjugate ladiratuzumab vedotin worldwide; and another to accelerate the global reach of Tukysa (tucatinib).
In a deal valued at US$21bn, Gilead Sciences is to acquire Immunomedics Inc, a New Jersey headquartered biotech that has been highly focused on breast cancer drug innovation.
Pfizer and BioNTech plan to expand the enrolment of their Phase 3 pivotal COVID-19 vaccine trial to up to 44,000 participants: which will also include new populations.
Cytiva is to invest US$500m over the next five years to raise manufacturing capacity, hiring nearly 1,000 personnel in Austria, China, Singapore, Sweden, and the US, and bringing on new manufacturing lines, 24/7 shift patterns, and increased automation.
AstraZeneca has resumed UK clinical trials for its Oxford coronavirus vaccine, having paused all trials last week for a safety review. Other late-stage global trials, however, remain on hold while AstraZeneca waits for regulators in each market.
Transporting a COVID-19 vaccine to 7.8 billion people around the world would fill 8,000 jumbo jets – illustrating the enormity of the distribution challenge. The International Air Transport Association (IATA) warns of potential capacity constraints,...
